Site-agnostic cancer diagnosis technology for powering the site-agnostic cancer treatments
In healthy state, immunity kills and controls cancer throughout our body from head to toe. And the 2018 Nobel Prize-winning cancer immunotherapy drugs called checkpoint inhibitors proved that our immunity can be used in treating over 48% of all cancer cases throughout our body (Haslam and Prasad, 2019). Coined “site-agnostic” treatment, this new paradigm of immunity-based cancer treatment works independent of the anatomical location of cancer and results in cure if successful.
With continuing developments in cancer immunotherapy, medicine is approaching the idea of curing cancer of any locations without surgical intervention. And in this nearing future, early and successful diagnosis of cancer or its metastasis itself is the most important concern, rather than the determination of its anatomical location.
Based on the proven science of PKA Cα autoantibody for pan-cancer diagnosis (Nesterova et al., 2006; Cho 2006; Cho et al., 2000), Biogemex is delivering the very future: site-agnostic cancer diagnosis for powering site-agnostic cancer treatments. Successful translation of our technology will be instrumental in accelerating and improving the fidelity of the ongoing immunotherapy clinical investigations against metastatic breast cancer, ovarian, or prostate cancer among others.
BioGemex is focusing on the development of point-of-care (POC) diagnostic kit to detect PKA Cα autoantibody which can be conducted by TumorScreen. Thus, TumorScreen will be the first site-agnostic diagnosis for powering the latest breakthrough cancer clinical investigations.
Different expression of PKA C α autoantibody
Comparison of conventional and BGX’s novel biomarkers
|Conventional individual cancer diagnosis||BGX’s pan-cancer diagnosis|
|Cancer type||Cancer-specific||Pan-cancer monitoring|
|Detection method||Mostly qualitative||Quantitative|
|Accuracy||Low specificity and High sensitivity||High specificity and sensitivity (tested via ELISA)
(will be validated with POC diagnostic, the TumorScreen)
|Early cancer detection (Y/N)||N||Y|
Tests and Assays planned for 2019 - 2020
|Product name||Biomarker||Detection methods(Status)||Indication in development|
|TumorScreen||Anti- PKA Cα antibody||ELISA & Rapid||High priority targets: ovarian cancer, prostate cancer, breast cancer|
|TumorScreen (Ver2)||Anti- PKA Cα antibody combination with other universal cancer biomarkers||Preclinical||Various cancers|
Instruments/devices planned for 2019 -2021
|TumorScreen single reader||Quantification of Anti- PKA Cα antibody|
|BG product semi/full automation||Automation reader system to conduct BG’s diagnostic test series|